首页> 美国卫生研究院文献>AAPS PharmSciTech >Variation Transmission Model for Setting Acceptance Criteria in a Multi-staged Pharmaceutical Manufacturing Process
【2h】

Variation Transmission Model for Setting Acceptance Criteria in a Multi-staged Pharmaceutical Manufacturing Process

机译:在多阶段药物制造过程中设定接受标准的变异传递模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pharmaceutical manufacturing processes consist of a series of stages (e.g., reaction, workup, isolation) to generate the active pharmaceutical ingredient (API). Outputs at intermediate stages (in-process control) and API need to be controlled within acceptance criteria to assure final drug product quality. In this paper, two methods based on tolerance interval to derive such acceptance criteria will be evaluated. The first method is serial worst case (SWC), an industry risk minimization strategy, wherein input materials and process parameters of a stage are fixed at their worst-case settings to calculate the maximum level expected from the stage. This maximum output then becomes input to the next stage wherein process parameters are again fixed at worst-case setting. The procedure is serially repeated throughout the process until the final stage. The calculated limits using SWC can be artificially high and may not reflect the actual process performance. The second method is the variation transmission (VT) using autoregressive model, wherein variation transmitted up to a stage is estimated by accounting for the recursive structure of the errors at each stage. Computer simulations at varying extent of variation transmission and process stage variability are performed. For the scenarios tested, VT method is demonstrated to better maintain the simulated confidence level and more precisely estimate the true proportion parameter than SWC. Real data examples are also presented that corroborate the findings from the simulation. Overall, VT is recommended for setting acceptance criteria in a multi-staged pharmaceutical manufacturing process.
机译:药物制造过程包括一系列步骤(例如反应,后处理,分离),以产生活性药物成分(API)。中间阶段(过程控制)和API的输出需要控制在可接受的标准范围内,以确保最终药品的质量。在本文中,将评估两种基于公差区间得出此类接受标准的方法。第一种方法是串行最坏情况(SWC),这是一种行业风险最小化策略,其中,阶段的输入材料和过程参数固定在其最坏情况设置下,以计算该阶段期望的最大级别。然后,该最大输出将输入到下一级,在该下一级,工艺参数再次固定为最坏情况下的设置。在整个过程中将顺序重复此过程,直到最后阶段。使用SWC计算得出的极限可能是人为的,可能无法反映实际的过程性能。第二种方法是使用自回归模型的变异传递(VT),其中通过考虑每个阶段的错误的递归结构来估算传递到某个阶段的变异。进行变化程度变化和过程阶段变化的计算机模拟。对于所测试的场景,与SWC相比,VT方法被证明可以更好地维持模拟的置信度并更精确地估计真实比例参数。还提供了真实的数据示例,这些数据证实了仿真的结果。总体而言,建议在多阶段药物制造过程中使用VT设置接受标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号